Allogene Therapeutics is making unexpected changes to development plans for its off-the-shelf cell therapy for a type of blood cancer — a concession that competition from personalized CAR-T treatments, already entrenched in the market, has become more challenging.
In a strategic pivot, two clinical trials involving patients with later-stage lymphoma are being shut down. The studies, open for more than a year, were intended to collect data and support the approval of Allogene’s therapy, called ALLO-501A.
Instead, Allogene plans to conduct an entirely new study of ALLO-501A in patients with newly diagnosed lymphoma at higher risk of relapse.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect